NCT04485559 2026-03-16
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
Phase 1 Recruiting
Clinical Trials
23 trialsNCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT05843253 2026-03-04
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT04199026 2026-02-19
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT06955169 2026-02-17
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
NCT05476939 2026-02-05
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT05432518 2025-04-25
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Phase EARLY_PHASE1 Recruiting
NCT06126588 2025-03-11
ELUMEN
Central Hospital, Nancy, France
Phase 2 Recruiting
NCT02432560 2024-12-24
MIDAS
University of Cincinnati
Recruiting
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05833815 2024-08-13
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
Banaras Hindu University
Phase 2/3 Recruiting
NCT04803318 2024-06-25
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06472388 2024-06-25
EVENET
AC Camargo Cancer Center
Phase 2 Recruiting
NCT06317298 2024-03-19
Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy
Peking University First Hospital
Phase NA Recruiting
NCT05949541 2024-02-08
BCTOP-L-M01
Fudan University
Phase 2 Recruiting
NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
NCT05954442 2024-01-16
BCTOP-T-M03
Fudan University
Phase 3 Recruiting
NCT05983107 2023-08-09
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting